



e-ISSN: 2319-8753 | p-ISSN: 2347-6710

# IJIRSET

International Journal of Innovative Research in  
**SCIENCE | ENGINEERING | TECHNOLOGY**



# INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

Volume 11, Issue 9, September 2022

**ISSN** INTERNATIONAL  
STANDARD  
SERIAL  
NUMBER  
INDIA

Impact Factor: 8.118



9940 572 462



6381 907 438



ijirset@gmail.com



www.ijirset.com

# Neural Plasticity in Space-Related Neuropsychiatric Disease and Injury: A Review

Dr Debopriya Ghosh, Dr Ekta Verma, Mr. Romel Kumar Ghosh, Mr. Paul Anderson,

Dr Stephen Gershman,

Department of Physiology, University College of Medical Sciences. Delhi, India.

Department of Paediatrics, All India Institute of medical Sciences, Gorakhpur, India.

University of Calcutta, Kolkata, India.

Department of Biomedical Engineering, Virginia Commonwealth University, USA

Department of Neuroscience, University of Alberta, Canada.

**ABSTRACT:** Next-generation space medical advancements are presently driven by increased government and industry initiatives to plan and deliver feasible manned near-to-deep solar system exploration and habitation during the coming decades. The use of advanced precision medical techniques, such as brain stimulation, offers effective clinical and field/flight situation methods to selectively control vagal tone and neuroendocrine-modulated corticolimbic plasticity, which are impacted by prolonged cosmic radiation exposure, social isolation or crowding, and weightlessness in constrained operational non-terran locales. Earth-based clinical research shows that brain stimulation techniques can be used in conjunction with cutting-edge psychotherapeutic integrated memory structure theories to improve neuropsychiatric patient outcomes by corrective reconsolidation of arousing or emotional experiences, autobiographical memories, semantic schema, and other cognitive structures. These clever cotherapies or countermeasures, which take advantage of naturally occurring, pharmaceutically induced, and minimally invasive nervous system activity, may optimise the cognitive-emotional restructuring of astronauts suffering from space-related neuropsychiatric disease and injury, including mood, affect, and anxiety symptoms of any potential severity and pathophysiology. Deeper understanding of the illness states experienced by astronauts can be gained by appreciating improved neuropsychiatric healthcare through the fusion of new or rediscovered smart theragnostic medical technologies, capable of providing individualised neuroplasticity training and managed psychotherapeutic treatment protocols. Future research in this field should place a strong emphasis on the moral obligations of telemedicine and/or digital clinicians to advance (semi-)autonomous, technology-assisted medical prophylaxis, diagnosis, treatment, monitoring, and compliance of astronauts for improved health, safety, and performance in remote extreme space and extraterrestrial environments.

**KEYWORDS:** Astronaut Health, Cognitive-Emotional Reorganisation, Corticolimbic Plasticity, Neuropsychiatric Illness And Injury, Advanced Medical Technology, And Space Therapeutics

## I. INTRODUCTION

To start and finish even routine daily mission tasks and housing requirements in extraterrestrial conditions effectively, spaceflight-engaged astronauts frequently must execute with sustained high levels of physical, mental, emotional, and social competency. Stress brought on by prolonged exposure to severe environments, such as high-dose cosmic radiation, microgravity, and social isolation or crowding in small working spaces, increases hazards to astronauts' health, safety, and welfare and complicates already difficult mission objectives. In order to advance NASA's objectives for manned near-to-deep solar system exploration, the 2020 National Aeronautics and Space Administration (NASA) Technology Taxonomy roadmap continues to emphasise the importance of research and development into, and the application of, technologies and methods that improve human health, life support, and habitation in space and extraterrestrial environments. Medical diagnosis and prognosis, preventive and defence, behavioural health and performance, contactless and wearable human health and performance monitoring, long-duration health, and system

transformational health and performance ideas are only a few of the specific areas of interest. These areas of focus are examined here in the context of neuropsychiatric insults, such as mood, affect, anxiety, personality, and psychotic problems [1–10], since spaceflight, gateway, and non-terran satellite/planetary surface circumstances change astronauts' neurobiology and psychology. It is thought that clever theragnostic cognitive-emotional restructuring can be used to reduce the detrimental impact that space exposure has on an astronaut's performance and mental health. Analog and real space investigations must be carried out to confirm the acceptability and efficacy of these kinds of therapies as plans for more short- to long-duration commercial space events, such as the recent SpaceX civilian Inspiration4 mission, and joint government-industry events, such as those of NASA's Artemis programme, continue to advance. For instance, the Artemis programme aims to land the second man and the first woman on the Moon from a lunar orbit Gateway over the course of the next ten years, establish a sustained human presence on the Moon by 2028, and further develop technologies, capabilities, and business plans for upcoming successful crewed spaceflight missions to Mars and other locations. The dangers involved with these tasks need more focus on the mental health of astronauts as well as the development and use of new techniques for monitoring, diagnosing, and treating medical emergencies in isolated space settings. In space travel and habitation, emotions and the arousing sensations that go along with them can weaken or strengthen the storage and retrieval of human memories, depending on the degree of intensity and associativity to autobiographical episodes and declarative knowledge. This has an impact on cognitive, social, and physical performance. Extreme emotional events and the memories that follow from them may also become maladaptive, leading to neuropsychiatric issues whether they vividly enter or stay inaccessible to human awareness, making astronauts susceptible to poor mental health outcomes in extraterrestrial environments. Lane et al. [11] and other professionals (such as [12,13]) have compiled appealing, albeit somewhat preliminary, psychotherapeutic strategies that (Earth) clinicians are now further researching. These strategies rely on carefully choosing which integrated memory structures of patients to reconsolidate. Clinicians will be better able to recognise and treat mood, affect, and anxiety disorders as well as the effects of traumatic brain injury with the help of these modified cognitive structures, which include (implicit/explicit) emotional responses, autobiographical memories, semantic schema, and other cognitive structures. Some of these programmes aim to use the Yerkes-Dodson law of arousal-modulated performance within (mental/physical) situational contexts to (1) recover or uncover patient memories of emotional traumas and (2) associate and then reconsolidate corrective cognitive representations and emotional responses with the same target memories through the appropriate use of a single single. The notion in its current form is plagued by methodological imprecision for Earth-based clinical effectiveness and compliance, despite the fact that this sort of methodology is inspired by well-established clinical and fundamental neuroscience research findings on memory modulation [14-24]. Such issues are prevalent in other purely psychotherapy approaches, and integrated memory structure rationales may only achieve the maximum clinical results in individuals with mild to moderate neuropsychiatric symptoms, even after revision. Situational challenges in locating and providing astronauts with neuropsychiatric diagnostic and treatment options further complicate issues for clinical success. Psychotherapeutic approaches may be appropriately optimised with the co-application of repurposed, newly emerging, and next-generation smart computer-interfaced theragnostic medical devices linked to assistive telemedicine technologies and medical social robot or virtual digibot therapists to overcome such gaps in medical prophylaxis, diagnosis, treatment, monitoring, and compliance. The prognosis for astronauts' mental health in alien conditions, such as space, as well as on Earth after their return will probably be improved by trends in cutting-edge therapeutics. Benefits from these improved theragnostic strategies may also be used to support innovative changes in health care for civilian populations on Earth who are exposed to growing challenges (such as extreme Earth environments, longer human lifespans, denser human populations and overcrowding, increased human desocialization or conflict, etc.), which may worsen mental health in a demographic group-dependent and/or -independent manner. Successes in translational medicine in the past, like NASA's involvement in bringing telemedicine to Earth-based medicine and underserved communities, may serve as models to change current trends in these fields, leading to more affordable, accessible, and efficient Earth medical policies and practises.

## II. CHALLENGES RELATED TO COGNITIVE-EMOTIONAL RECONSTRUCTION

Physical activity, mental stimulation, and social support are common remedies for poor astronaut mental health. More study is required to understand how non-terran settings can affect the safety and efficacy of such therapeutic approaches, although neurotechnology and other-apy alternatives created for Earthlings may still apply to space travellers. Alternative neuropsychiatric techniques (as mentioned above) ignore how ground and flight physicians or coming smart medical social robots (cf. [25,26]) can produce treatment effectiveness that is closer to ideal. The Paro, eBear, Kaspar, Nao, and RoboTherapy companion robots as well as the Tess, Sara, Wysa, and Woebot digibots are current examples of inexpensive, accessible digital gadgets with strong therapeutic potential. These interactive meta-

learning inferential devices, which communicate with patients via interpretable speech and text, offer sound remote (semi)autonomous smart assistive substitute healthcare solutions for patients who are experiencing symptoms of social isolation and stress, which are comparable to those related to the work and living conditions of space missions. They can be more successful, yet many psychotherapy techniques have not yet been tested on them. One key tactic is to combine the benefits of minimally invasive smart neuroprosthetic technologies, such as (1) vagus nerve stimulation (VNS), (2) transcranial electrical stimulation (TES), (3) transcranial near-infrared stimulation (TIRS), (4) transcranial magnetic stimulation (TMS), and (5) emerging smart pharmaceuticals, such as microRNA-targeting mimics, antagomirs, and antagonists, with digitally delivered psychotherapy and integrated memory structure rationales. For the treatment of mood, affective, and anxiety disorders that are currently resistant to traditional medication treatments and/or psychotherapy methods, several of these smart medical technologies are now commercially accessible or in the process of being developed. The frequently labile, progressive, and irreversible expression of forebrain pathophysiology in some of the most severe mental illnesses makes patients refractory to otherwise well-known, safe (and bearable), disease prophylaxes, management, and therapies. Even patient populations on Earth with mild to severe psychiatric diseases, such as chronic depression and tier-specific post-traumatic stress disorder, react to psychotherapy, chemotherapy, or combination psychotherapy/chemotherapy with considerable rates of chronic and acute symptom recurrence [40,41]. For patients displaying complex emotional components, integrated memory structure rationales aim to enhance the efficacy of regular psychotherapy, especially since it reduces the problematic heterogeneity of psychotherapy choice and delivery (e.g., poor psychotherapeutic entry points, client-clinician rapport, patient compliance, trauma identification and schema restructuring, etc. However, a lot of doctors who endorse the rationales for integrated memory structures noticeably omit to specify how to establish and maintain appropriate, therapeutic (i.e., moderate) levels of patient arousal in therapeutic settings. Additionally, they frequently fail to properly take into account illnesses for which these programmes may only have limited effectiveness, such as cognitive-behavioral deficits coupled with substantial persisting anatomical and functional abnormalities in the corticolimbic system.

### III. ADVANCED SOLUTION OF CHALLENGES

In both theory and practise, the process of reforming and reactivating memories in order to achieve cognitive-emotional restructuring in patients necessitates extremely regulated physiological conditions of either healthy or (remedied) diseased nerve systems. Modern smart precision medicine may give space medicine practitioners the crucial clinical tools they need to fix these problems by using integrated memory structure justifications and, as a result, boost their therapeutic potential. Smart neuroprosthetics and drug delivery systems can be used to treat many neuropathologies seen in the hippocampus, amygdala, medial prefrontal, and cingulate cortices (cf. [14,28,32,33,42-45]) by acting via highly selective substrate and temporal targeting of disease-affiliated molecules, cellular organelles and pathways, brain networks, and nerve fibre groups. These pathologies relate to mood, affective, and anxiety disorders as well as hypoxic and ischemic brain damage, and include, among other things, (1) disturbances in neuro- and synaptogenesis, (2) protein expression, (3) neuronal excitotoxicity and glial proliferation, and (4) glucocorticoid-dependent neurotrophic factor concentrations. Through focused neuroplasticity training, these cutting-edge technologies not only compensate for coexisting neurological conditions but also successfully change patient learning, memory, and executive function (e.g., [14,15,31,46-48]). The signal-to-noise ratio of neurotransmission (e.g., [14,53]), brain synaptic plasticity (e.g., [14,44,45,49,50]), single-unit and field potential phasic activity (e.g., [14,51,52]), and neurotransmitter synthesis, release, and re-uptake (e.g., [14,54,55]) are all altered by targeted neuroplasticity training.

### IV. TMS AND COGNITIVE-EMOTIONAL RECONSTRUCTION

The more or less direct biological link between the production and recall of traumatic emotional experiences makes the use of VNS to promote cognitive-emotional reorganisation in astronauts appealing. By directly enhancing or imitating neural communication and the (structural and functional) connectivity between the limbic and cortical areas, TMS, another potentially effective treatment adjuvant, may also help patients with cognitive-emotional restructuring, assisting with memory consolidation and retrieval (cf. [83-88]). Since TMS avoids enlisting the vagal system, it should be assumed that the corticolimbic plasticity caused by precise TMS alone is less reflective of the biological processes and brain alterations that normally follow emotional events than VNS. TMS has nevertheless been demonstrated to be a reliable method for altering the accuracy and storage capacity, retrieval, and/or reconsolidation of emotional memories in animal models of anxiety, as well as in people who have experienced emotional trauma in real life or who are subjected to artificially induced emotional situations (e.g., [89-94]). TMS has shown impressive success in modifying

memory characteristics and performance levels that are specific to a patient's sensorial/perceptual modalities, gender, degree of attention, and emotional, semantic, and procedural content of patient memories [95–101]. This has encouraged its use in the treatment of a variety of psychiatric conditions, including schizophrenia, major depression, dementia, post-traumatic stress disorder, and other psychiatric disorders (e.g., [102–109]). Though the targeted phenomenological effects of TMS on patients' memory and cognition, and consequently their psychiatric status, are largely the result of physiological tuning and the reorganisation of lower-band brain function, frequently through large-scale network interference or facilitation (cf. [109–114]), the cytological and biochemical mechanisms mediating such plasticity are only now being clarified. According to preliminary sets of findings, TMS alters synaptic transmission, as well as corresponding synaptic structure and density, in a manner that is intensity-specific, similar to VNS, and that these changes are caused by altered brain concentrations of (1) amino acid and bioamine neurotransmitters, (2) neurotrophic factors, and (3) protein kinase-dependent kinase-dependent protein synthesis, transcription, and cell metabolism and growth [115–120]. Together, these and other data suggest that the use of TMS in conjunction with psychotherapeutic techniques offers a secure, effective means of achieving cognitive-emotional reorganisation in Earth patients (e.g., [121]), and maybe astronauts.

## V. FUTURE ASPECTS

The use of cutting-edge smart precision medicine will inevitably improve psychotherapeutic integrated memory structure rationales for the corrective reconsolidation of traumatic arousing or emotional experiences, autobiographical memories, and semantic schema. With the aid of neuroprosthesis-driven VNS or TMS, for instance, physicians may use these justifications to target specific vagal tone and psychiatric trauma-related brain processes for a more individualised, effective, noninvasive approach to treating mood, affective, and anxiety disorders. Existing neurotechnologies can be quickly and affordably adapted for use in space medicine without adding significant weight to the payload or placing a significant burden on the health, life support, or habitation systems. Instead, choices among commercially available small portable stimulation and wearable monitoring devices made for Earth-based clinical treatment of various neuropsychiatric and motor indications are available. These kinds of devices may be fitted with minimally invasive contact or contactless sensor/stimulator-connected computer interfaces, which can be programmed with user-friendly proprietary software, even though legal, regulatory, and ethical issues still exist for Earth medical policies and practises (e.g., [25,26,122,123]). To diagnose, treat, and monitor patients based on a variety of smart real-time biomarker data analytics and electronic record keeping (e.g., [59,124–127]), these systems may also be linked with (ultraparanoic computing) encrypted semi-autonomous or autonomous mobile or stationary virtual remote medicine systems. These systems may include, but are not limited to, those associated with typical physiological vital signs, brain function, and continuous body fluid chemical profiles. Although these benefits of space deployment, psychotherapy techniques require clinician-completed patient evaluations, such as semi-structured and structured inventories that are standardised in the industry, and clinician-led treatment sessions in order to maximise patient outcomes. Neurotechnologies must smoothly and cooperatively integrate clever human-emulating social medical robots or virtual digibot therapists to carry out interactive psychotherapy in conjunction with the operation of neuro-cybernetic prosthetic systems in the absence of human clinical practitioners. Artificially intelligent, deep-learning, and meta-learning inferential digital therapists have undergone extensive development over many decades. This work has had a variety of positive effects on patient populations, from paediatric to geriatric cohorts, in terms of their mental health and wellbeing (e.g., [25,26,122,123]). These technologies are shown by successful results recorded for the previously covered social robots and digibots [122], which may be telemedically connected via neurocybernetic prosthetic command and control systems for optimum VNS or TMS administration. To improve patient outcomes both on Earth and in environments beyond Earth, research and development must focus on enhancing the safety, efficacy, and clinician-patient relationship of digital therapists. Despite this, progress in this field is still modest. The use of more potent, internally and externally valid, precise psychological, biological, behavioural, and digital biomarkers as well as more dependable and accurate fast theragnostic computational models that better manage data workloads/-flows for better patient therapy experiences as well as personalised mental health diagnosis and monitoring are some current observable gaps in the state-of-the-art systems. While promising computational model examples include feature classifier/extraction/prediction algorithms capable of adaptive quasi-model-free/-based neural net embedding, trainable distributed cognition-emotion mapping, and artificial (surrogate th)earing, promising disease marker examples include constellations incorporating acoustic, structural, and semantic language production, use, and comprehension to detect the onset and severity of neuropsychiatric conditions [128–134]. Many of these artificial intelligence and machine learning milestones are still being stressed in the competitive biotechnology and medical commercial sectors based on

Earth, and they could realistically be accomplished over the next five to eight years with safe, effective deployment for suitable space and extraterrestrial utility within the decade [134].

## VI. CONCLUSION

In the coming ten years, committed research and development by the private sector, the public sector, and academia will significantly advance these emerging technologies and their clinical application, including the successful integration of artificial surrogate-mediated therapeutic approaches with intelligent interoperable pharmaceutical and other treatment delivery systems [1,133]. This future requires appropriate government and business control of technological efficacy, privacy, and security. The seamless, high-quality deployment of intelligent artificial surrogate clinicians for both Earth and space medicine objectives depends on rigorous, transparent dialogue regarding appropriate technology-assisted medical information storage and utilisation. Such extensive, well-coordinated community activities promote cultural comprehension of the benefits of intelligent technologies, both medically and economically, and the societal role they play. They also encourage and maintain consumer confidence and good patient-provider relationships. In order to decide if and which artificially intelligent surrogate clinician technologies should be subject to standard healthcare technology regulatory examination and approval, more precise, enforceable rules [25,26,121-123,132-135] must be developed. The establishment of best policies and practises for educating healthcare providers on the use of technology in various healthcare models, professional organisation recommendations, satisfying duties of care, reporting harm, and providing reliable pathways for risk assessment and service referral are just a few topics that guidelines may cover. Transparency in technology supervision and services that respect patient autonomy, vulnerability, and privacy, the examination and mitigation of institutionalised and personal biases that result in unwelcome disparities in the delivery of technology and services; and A few examples of inequities are (1) the state of diagnostic validation, (2) the availability of free platforms for obtaining and sharing digital biomarker data, (3) the suitability of behavioural and digital phenotyping, (4) the depth of data-driven learning engines, (5) the use of real-world evidence, (6) the expense and infrastructure for data storage and analysis, (g) seamless data integration with clinical records, and (7) policed data ownership and protection.

## REFERENCES

1. Clark, K.B. Topical: Smart Theragnostic Cognitive-Emotional Restructuring for Space-Related Neuropsychiatric Disease and Injury. White Paper Submitted to the Committee on the Decadal Survey for Biological and Physical Sciences Research in Space 2023-2032; National Research Council: Washington, DC, USA, in press.
2. Jandial, R.; Hoshide, R.; Waters, J.D.; Limoli, C.L. Space-brain: The negative effects of space exposure on the central nervous system. *Surg. Neurol. Int.* 2018, 9, 9. [CrossRef]
3. Kanas, N. Psychological, psychiatric, and interpersonal aspects of long-term space missions. *J. Spacecr. Rockets* 2018, 27, 457–463. [CrossRef]
4. Kanas, N. Psychosocial value of space simulation for extended spaceflight. *Adv. Space Biol. Med.* 1997, 6, 81–91. [CrossRef] [PubMed]
5. Mann, V.; Sundaresan, A.; Chaganti, M. Cellular changes in the nervous system to gravitational variation. *Neurol. India* 2019, 67, 684–691. [CrossRef] [PubMed]
6. Marshall-Goebel, K.; Damanu, R.; Bershad, E.M. Brain physiological response and adaptation during spaceflight. *Neurosurgery* 2019, 85, E815–E821. [CrossRef] [PubMed]
7. Nday, C.M.; Frantzidis, C.; Jackson, G.; Bamidis, P.; Kourtidou-Papadeli, C. Neurophysiological changes in simulated microgravity: An animal model. *Neurol. India* 2019, 67, S221–S226. [CrossRef]
8. Ohuwafemi, F.A.; Abdelbaki, R.; Lai, J.C.-Y.; Mora-Almanza, J.G.; Afolavan, E.M. A review of astronaut mental health in manned missions: Potential interventions for cognitive and mental challenges. *Life Sci. Space Res.* 2021, 28, 26–31. [CrossRef]
9. Romanella, S.M.; Sprugnoli, G.; Ruffini, G.; Sevedmadam, K.; Rossi, S.; Santarneckchi, E. Noninvasive brain stimulation & space exploration: Opportunities and challenges. *Neurosci. Biobehav. Rev.* 2020, 119, 294–319. [CrossRef]
10. Roy-O'Reilly, M.; Mulavara, A.; Williams, T. A review of alterations to the brain during spaceflight and the potential relevance to crew in long-duration space exploration. *NPJ Microgravity* 2021, 7, 5. [CrossRef]
11. Lane, R.D.; Ryan, L.; Nadel, L.; Greenberg, L. Memory reconsolidation, emotional arousal and the process of change in psychotherapy: New insights from brain science. *Behav. Brain Sci.* 2014, 38, e1. [CrossRef]

12. Helmsick, K. Cognitive rehabilitation for military personnel with mild traumatic brain injury and chronic post-concussional disorder: Results of April 2009 consensus conference. *NeuroRehabilitation* 2010, 26, 239–255. [CrossRef] [PubMed]
13. Kumar, K.; Samuelkamaleshkumar, S.; Viswanathan, A.; Macaden, A. Cognitive rehabilitation for adults with traumatic brain injury to improve occupational outcomes. *Cochrane Database Syst. Rev.* 2017, 6, CD007935. [CrossRef] [PubMed]
14. Clark, K.B. Studies Investigating the Role Played by Vagus Nerve Stimulation in the Modulation of Memory Formation. Ph.D. Thesis, Southern Illinois University, Carbondale, IL, USA, 1999.
15. Clark, K.B.; Naritoku, D.K.; Smith, D.C.; Browning, R.A.; Jensen, R.A. Enhanced recognition memory following vagus nerve stimulation in human subjects. *Nat. Neurosci.* 1999, 2, 94–98. [CrossRef]
16. McGaugh, J.L. *Memory and Emotion: The Making of Lasting Memories*; Columbia University Press: New York, NY, USA, 2003; ISBN-13: 978-0231120234.
17. McIntyre, C.K.; McGaugh, J.L.; Williams, C.L. Interacting brain systems modulate memory consolidation. *Neurosci. Biobehav. Rev.* 2012, 36, 1750–1762. [CrossRef] [PubMed]
18. Nadel, L.; Samsonovich, A.; Ryan, L.; Moscovitch, M. Multiple trace theory of human memory: Computational, neuroimaging, and neuropsychological results. *Hippocampus* 2000, 10, 352–368. [CrossRef]
19. Nadel, L.; Campbell, J.; Ryan, L. Autobiographical memory retrieval and hippocampal activation as a function of repetition and the passage of time. *Neural. Plast.* 2007, 2007, 90472. [CrossRef]
20. Nader, K.; Schafe, G.E.; Le Doux, J.E. Reconsolidation: The labile nature of consolidation theory. *Nat. Rev. Neurosci.* 2000, 1, 216–219. [CrossRef]
21. Phelps, E.A. Human emotion and memory: Interactions of the amygdala and hippocampal complex. *Curr. Opin. Neurobiol.* 2004, 14, 198–202. [CrossRef]
22. Roozendaal, B.; McEwen, B.S.; Chattarji, S. Stress, memory and the amygdale. *Nat. Rev. Neurosci.* 2009, 10, 423–433. [CrossRef]
23. Williams, C.L.; Jensen, R.A. Effects of vagotomy on Leu-enkephalin-induced changes in memory storage processes. *Physiol. Behav.* 1993, 54, 659–663. [CrossRef]
24. Wilson, M.A.; McNaughton, B.L. Reactivation of hippocampal ensemble memories during sleep. *Science* 1994, 265, 676–679. [CrossRef]
25. Clark, K.B. The humanness of artificial nonnormative personalities. *Behav. Brain Sci.* 2017, 40, e259. [CrossRef]
26. Clark, K.B. Digital life, a theory of minds, and mapping human and machine cultural universals. *Behav. Brain Sci.* 2020, 43, e98. [CrossRef] [PubMed]
27. Hays, S.A.; Rennaker, R.L.; Kilgard, M.P. Targeting plasticity with vagus nerve stimulation to treat neurological disease. *Prog. Brain Res.* 2013, 207, 275–299. [CrossRef]
28. Howland, R.H.; Shutt, L.S.; Berman, S.R.; Spots, C.R.; Denko, T. The emerging use of technology for the treatment of depression and other neuropsychiatric disorders. *Ann. Clin. Psychiatry* 2011, 23, 48–62. [PubMed]
29. Naritoku, D.N.; Jensen, R.A.; Browning, R.A.; Clark, K.B.; Smith, D.C.; Terry, R.S., Jr. Methods of Modulating Aspects of Brain Neural Plasticity by Vagus Nerve Stimulation. U.S. Patent 6339725, 15 January 2002. Available online: <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnethtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6,339,725.PN.&OS=PN/6,339,725&RS=PN/6,339,725> (accessed on 10 December 2021).
30. Naritoku, D.K.; Jensen, R.A.; Browning, R.A.; Clark, K.B.; Smith, D.C.; Terry, R.S., Jr. Methods of Improving Learning or Memory by Vagus Nerve Stimulation. U.S. Patent 6556868, 29 April 2003. Available online: <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnethtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6,556,868.PN.&OS=PN/6,556,868&RS=PN/6,556,868> (accessed on 10 December 2021).
31. Peña, D.F.; Engineer, N.D.; McIntyre, C.K. Rapid remission of conditioned fear expression with extinction training paired with vagus nerve stimulation. *Biol. Psychiatry* 2013, 73, 1071–1077. [CrossRef]

32. Agyare, E.K.; Curran, G.L.; Ramakrishnan, M.; Yu, C.C.; Poduslo, J.F.; Kandimalla, K.K. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. *Pharm. Res.* 2008, 25, 2674–2684. [CrossRef] [PubMed]
33. Dinan, T.G. MicroRNAs as a target for novel antipsychotic: A systematic review of an emerging field. *Int. J. Neuropsychopharmacol.* 2010, 13, 395–404. [CrossRef] [PubMed]
34. Modi, G.; Pillay, V.; Choonara, Y.E. Advances in the treatment of neurodegenerative disorders employing nanotechnology. *Ann. N. Y. Acad. Sci.* 2010, 1184, 154–172. [CrossRef] [PubMed]
35. De Oliveria Barros, A.; Yang, J. A review of magnetically actuated milli/micro-scale robots locomotion and features. *Crit. Rev. Biomed. Eng.* 2019, 47, 379–394. [CrossRef] [PubMed]
36. Nummelin, S.; Shen, B.; Piskunen, P.; Liu, Q.; Kostianen, M.A.; Linko, V. Robotic DNA nanostructures. *ACS Synth. Biol.* 2020, 9, 1923–1940. [CrossRef]
37. Li, M.; Xi, N.; Wang, Y.; Liu, L. Progress in Nanorobotics for Advancing Biomedicine. *IEEE Trans. Biomed. Eng.* 2021, 68, 130–147. [CrossRef] [PubMed]
38. Pedram, A.; Pishkenari, H.N. Smart micro/nano-robotic systems for gene delivery. *Curr. Gene Ther.* 2017, 17, 73–79. [CrossRef] [PubMed]
39. Sun, L.; Yu, Y.; Chen, Z.; Bian, F.; Ye, F.; Sun, L.; Zhao, Y. Biohybrid robotics with living cell actuation. *Chem. Soc. Rev.* 2020, 49, 4043–4069. [CrossRef] [PubMed]
40. Hetrick, S.E.; Purcell, R.; Garner, B.; Parslow, R. Combined pharmacotherapy and psychological therapies for post-traumatic stress disorder (PTSD). *Cochrane Database Sys. Rev.* 2010, 7, CD007316. [CrossRef]
41. Von Wolff, A.; Hölzel, L.P.; Westphal, A.; Härter, M.; Kriston, L. Combination pharmacotherapy and psychotherapy in the treatment of chronic depression: A systematic review and meta-analysis. *BMC Psychiatry* 2012, 12, 61. [CrossRef]
42. Frasinim, M.; Puligheddu, M.; Demuru, M.; Polizzi, L.; Maleci, A.; Tamburini, G.; Congia, S.; Bortolato, M.; Marrosu, F. VNS induced desynchronization in gamma bands correlates with positive clinical outcomes in temporal lobe pharmacoresistant epilepsy. *Neurosci. Lett.* 2013, 536, 14–18. [CrossRef]
43. Lyubashina, O.; Panteleev, S. Effects of cervical vagus nerve stimulation on amygdala-evoked responses of the medial prefrontal cortex neurons in rat. *Neurosci. Res.* 2009, 65, 122–125. [CrossRef]
44. Nahas, Z.; Teneback, C.; Chae, J.H.; Mu, Q.; Molnar, C.; Kozel, F.A.; Walker, J.; Anderson, B.; Koola, J.; Kose, S.; et al. Serial vagus nerve stimulation functional MRI in treatment-resistant depression. *Neuropsychopharmacology* 2007, 32, 1649–1660. [CrossRef]
45. Roosevelt, R.W.; Smith, D.C.; Clough, R.W.; Jensen, R.A.; Browning, R.A. Increased extracellular concentrations of norepinephrine in cortex and hippocampus following vagus nerve stimulation in the rat. *Brain Res.* 2006, 1119, 124–132. [CrossRef] [PubMed]
46. Clark, K.B.; Kahl, S.E.; Smith, D.C.; Jensen, R.A. Post-training unilateral vagal stimulation enhances retention performance in the rat. *Neurobiol. Learn. Mem.* 1995, 63, 213–216. [CrossRef] [PubMed]
47. Clark, K.B.; Smith, D.C.; Hassert, D.L.; Browning, R.A.; Naritoku, D.K.; Jensen, R.A. Posttraining electrical stimulation of vagal afferents with concomitant efferent inactivation enhances memory storage processes in the rat. *Neurobiol. Learn. Mem.* 1998, 70, 364–373. [CrossRef]
48. Critchley, H.D.; Lewis, P.A.; Orth, M.; Josephs, O.; Deichmann, R.; Trimble, M.R.; Dolan, R.J. Vagus nerve stimulation for treatment-resistant depression: Behavioural and neural effects on encoding negative material. *Psychosom. Med.* 2007, 69, 17–22. [CrossRef]
49. Clark, K.B.; Smith, D.C.; Jensen, R.A. Vagus nerve stimulation induces both long-term potentiation and depression in the rat hippocampus. *Soc. Neurosci. Abstr.* 1997, 23, 787.
50. Zuo, Y.; Smith, D.C.; Jensen, R.A. Vagus nerve stimulation potentiates hippocampal LTP in freely-moving rats. *Physiol. Behav.* 2007, 90, 583–589. [CrossRef]
51. Clark, K.B.; Smith, D.C.; Browning, R.A. Long-term continuous, intermittent vagus nerve stimulation produces nerve adaptation that may suppress seizures. *Soc. Neurosci. Abstr.* 1998, 24, 718.
52. Usami, K.; Kano, R.; Kawai, K.; Noda, T.; Shiramatsu, T.I.; Saito, N.; Takahashi, H. Modulation of cortical synchrony by vagus nerve stimulation in adult rats. *Annu. Int. Conf. Proc. IEEE Eng. Med. Biol. Soc.* 2013, 2013, 5348–5351. [CrossRef]
53. Kahl, S.E.; Clark, K.B.; Smith, D.C.; Browning, R.A. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. *Epilepsia* 1998, 39, 709–714. [CrossRef] [PubMed]
54. Hassert, D.L.; Miyashita, T.; Williams, C.L. The effects of peripheral vagal nerve stimulation at a memory-modulating intensity on norepinephrine output in the basolateral amygdala. *Behav. Neurosci.* 2004, 118, 79–88. [CrossRef]

55. Krahel, S.E.; Clark, K.B. Vagus nerve stimulation for epilepsy: A review of central mechanisms. *Surg. Neurol. Int.* 2012, 3, S255–S259. [CrossRef]
56. Benchenane, K.; Peyrache, A.; Khamassi, M.; Tierney, P.L.; Gioanni, Y.; Battaglia, F.P.; Wiener, S.I. Coherent theta oscillations and reorganization of spike timing in the hippocampal-prefrontal network upon learning. *Neuron* 2010, 66, 921–936. [CrossRef]
57. Fisher, R.S. Therapeutic devices for epilepsy. *Ann. Neurol.* 2012, 71, 157–168. [CrossRef]
58. George, M.S.; Nahas, Z.; Borckardt, J.J.; Anderson, B.; Foust, M.J.; Burns, C.; Kose, S.; Short, E.B. Brain stimulation for the treatment of psychiatric disorders. *Curr. Opin. Psychiatry* 2007, 20, 250–254. [CrossRef]
59. Miranda, R.A.; Casebeer, W.D.; Hein, A.M.; Judy, J.W.; Krotkov, E.P.; Laabs, T.L.; Manzo, J.E.; Pankratz, K.G.; Pratt, G.A.; Sanchez, J.C.; et al. DARPA-funded efforts in the development of novel brain–computer interface technologies. *J. Neurosci. Methods* 2015, 244, 52–67. [CrossRef] [PubMed]
60. Barraco, I.R.A. (Ed.) . *Nucleus of the Solitary Tract*; CRC Press: Boca Raton, FL, USA, 1994.
61. Kalia, M.; Mesulam, M.-M. Brain stem projections of the sensory and motor components of the vagus complex in the cat: I. The cervical vagus and nodose ganglion. *J. Comp. Neurol.* 1980, 193, 467–508. [CrossRef]
62. Kalia, M.; Mesulam, M.-M. Brain stem projections of the sensory and motor components of the vagus complex in the cat: II. Laryngeal, tracheobronchial, pulmonary, cardiac, and gastrointestinal branches. *J. Comp. Neurol.* 1980, 193, 467–508. [CrossRef]
63. Ricardo, J.A.; Koh, E.T. Anatomical evidence for direct projections from the nucleus of the solitary tract to the hypothalamus, amygdala, and other forebrain structures in the rat. *Brain Res.* 1978, 153, 1–26. [CrossRef]
64. Rutecki, P. Anatomical, physiological, and theoretical basis for the antiepileptic effect of vagus nerve stimulation. *Epilepsia* 1990, 31, S1–S6. [CrossRef]
65. Aston-Jones, G.; Shipley, M.T.; Chouvert, G.; Ennis, M.; Van Bockstaele, E.; Pieribone, V.; Shiekhata, R.; Akaoka, H.; Drolet, G.; Astier, B.; et al. Afferent regulation of locus coeruleus neurons: Anatomy, physiology, and pharmacology. In *Progress in Brain Research: Neurobiology of the Locus Coeruleus*; Barnes, C.D., Pompeiano, O., Eds.; Elsevier: New York, NY, USA, 1991; Volume 88, pp. 47–75.
66. Ter Horst, G.J.; Streefland, C. Ascending projections of the solitary tract nucleus. In *Nucleus of the Solitary Tract*; Barraco, I.R.A., Ed.; CRC Press: Boca Raton, FL, USA, 1994; pp. 93–103.
67. Cornwall, J.; Cooper, J.D.; Phillipson, O.T. Afferent and efferent connections of the laterodorsal tegmental nucleus in the rat. *Br. Res. Bull.* 1990, 25, 271–284. [CrossRef]
68. Herbert, H.; Saper, C.B. Organization of medullary adrenergic and noradrenergic projections to the periaqueductal gray matter in the rat. *J. Comp. Neurol.* 1992, 315, 34–52. [CrossRef] [PubMed]
69. Ter Horst, G.J.; De Boer, P.; Luiten, P.G.M.; Van Willigen, J.D. Ascending projections from the solitary tract nucleus to the hypothalamus: A phaseolus vulgaris lectin tracing study in the rat. *Neuroscience* 1989, 31, 785–797. [CrossRef]
70. Cecchetto, D.F. Central representations of visceral function. *Fed. Proceed.* 1986, 46, 17–23.
71. Ferino, F.; Thierry, A.M.; Glowinski, J. Anatomical and electrophysiological evidence for a direct projection from Ammon's horn to the medial prefrontal cortex in the rat. *Exp. Brain Res.* 1987, 65, 421–426. [CrossRef]
72. Dorr, A.E.; Debonnel, G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. *J. Pharmacol. Exp. Ther.* 2006, 318, 890–898. [CrossRef]
73. Groves, D.A.; Bowman, E.M.; Brown, V.J. Recordings from the rat locus coeruleus during acute vagal nerve stimulation in the anaesthetised rat. *Neurosci. Lett.* 2005, 379, 174–179. [CrossRef]
74. Naritoku, D.K.; Terry, W.J.; Helfert, R.H. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. *Epilepsy Res.* 1995, 22, 53–62. [CrossRef]
75. Takigawa, M.; Mogenson, G.J. A study of inputs to antidromically identified neurons of the locus coeruleus. *Brain Res.* 1977, 135, 217–230. [CrossRef]
76. Garcia, R. Stress, metaplasticity, and antidepressants. *Curr. Mol. Med.* 2002, 2, 629–638. [CrossRef] [PubMed]
77. Young, T.; Bakish, D.; Beaulieu, S. The neurobiology of treatment response to antidepressants and mood stabilizing medications. *J. Psychiatry Neurosci.* 2002, 27, 260–265. [PubMed]
78. Masada, T.; Itano, T.; Fujisawa, M.; Miyamoto, O.; Tokuda, M.; Matsui, H.; Nagao, S.; Hatase, O. Protective effect of vagus nerve stimulation on forebrain ischaemia in gerbil hippocampus. *Neuroreport* 1996, 7, 446–448. [CrossRef]
79. Nishikawa, Y.; Koyama, N.; Yoshida, Y.; Yokota, T. Activation of ascending antinociceptive system by vagal afferent input as revealed in the nucleus ventralis posteromedialis. *Brain Res.* 1999, 833, 108–111. [CrossRef]

80. Browning, R.A.; Clark, K.B.; Naritoku, D.K.; Smith, D.C.; Jensen, R.A. Loss of anticonvulsant effect of vagus nerve stimulation in the pentylenetetrazol seizure model following treatment with 6-hydroxydopamine or 5,7-dihydroxytryptamine. *Soc. Neurosci. Abst.* 1997, 23, 2424.
81. Ben-Menachem, E.; Hamberger, A.; Hedner, T.; Hammond, E.J.; Uthman, B.M.; Slater, J.; Treig, T.; Stefan, H.; Ramsay, R.E.; Wernicke, J.F.; et al. Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. *Epilepsy Res.* 1995, 20, 221–227. [CrossRef]
82. Rush, A.J.; George, M.S.; Sackeim, H.A.; Marangell, L.B.; Husain, M.M.; Giller, C.; Nahas, Z.; Haines, S.; Simpson, R.K.; Goodman, R. Vagus nerve stimulation (VNS) for treatment-resistant depressions: A multicenter study. *Biol. Psychiatry* 2000, 47, 273–275. [CrossRef]
83. Brasil-Neto, J.P. Learning, memory, and transcranial direct current stimulation. *Front. Psychiatry* 2012, 3, 80. [CrossRef]
84. Breton, J.; Robertson, E.M. Flipping the switch: Mechanisms that regulate memory consolidation. *Trends Cogn. Sci.* 2014, 18, 629–634. [CrossRef]
85. Clark, V.P.; Parasuraman, R. Neuroenhancement: Enhancing brain and mind in health and in disease. *NeuroImage* 2014, 85, 889–894. [CrossRef]
86. George, M.S.; Massimini, M. Using brain stimulation to create thoughts, retrieve and alter memories, and measure consciousness—A discussion of research. *Brain Stim.* 2013, 6, 835–836. [CrossRef] [PubMed]
87. Robertson, E.M. New insights in human memory interference and consolidation, *Curr. Biol.* 2012, 22, R66–R71. [CrossRef]
88. Spiers, H.J.; Bendor, D. Enhance, delete, incept: Manipulating hippocampus-dependent memories. *Brain Res. Bull.* 2014, 105, 2–7. [CrossRef]
89. Baek, K.; Chae, J.H.; Jeong, J. The effect of repetitive transcranial magnetic stimulation on fear extinction in rats. *Neuroscience* 2012, 200, 159–165. [CrossRef] [PubMed]
90. Balconi, M.; Ferrari, C. rTMS stimulation on left DLPFC increases the correct recognition of memories for emotional target and distractor words. *Cogn. Affect. Behav. Neurosci.* 2012, 12, 589–598. [CrossRef]
91. Balconi, M.; Ferrari, C. Repeated transcranial magnetic stimulation on dorsolateral prefrontal cortex improves performance in emotional memory retrieval as a function of level of anxiety and stimulus valence. *Psychiatry Clin. Neurosci.* 2013, 67, 210–218. [CrossRef]
92. Balconi, M.; Ferrari, C. Left DLPFC rTMS stimulation reduced the anxiety bias effect or how to restore the positive memory processing in high-anxiety subjects. *Psychiatry Res.* 2013, 209, 554–559. [CrossRef] [PubMed]
93. Weigand, A.; Grimm, S.; Astalosch, A.; Guo, J.S.; Briesemeister, B.B.; Lisanby, S.H.; Luber, B.; Baiboui, M. Lateralized effects of prefrontal repetitive transcranial magnetic stimulation on emotional working memory. *Exp. Brain Res.* 2013, 227, 43–52. [CrossRef] [PubMed]
94. Weigand, A.; Richtermeier, A.; Feeser, M.; Guo, J.S.; Briesemeister, B.B.; Grimm, S.; Baiboui, M. State-dependent effects of prefrontal repetitive transcranial magnetic stimulation on emotional working memory. *Brain Stim.* 2013, 6, 905–912. [CrossRef]
95. Balconi, M.; Ferrari, C. Emotional memory retrieval. rTMS stimulation on the left DLPFC increases the positive memories. *Brain Imaging Behav.* 2012, 6, 454–461. [CrossRef]
96. Balconi, M.; Ferrari, C. rTMS stimulation on left DLPFC affects emotional cue retrieval as a function of anxiety level and gender. *Depress. Anxiety* 2012, 29, 976–982. [CrossRef] [PubMed]
97. Campanella, F.; Fabbro, F.; Ungesi, C. Cognitive and anatomical underpinnings of the conceptual knowledge for common objects and familiar people: A repetitive transcranial magnetic stimulation study. *PLoS ONE* 2013, 8, e64596. [CrossRef]
98. Censor, N.; Davan, E.; Cohen, L.G. Cortico-subcortico neuronal circuitry associated with reconsolidation of human procedural memories. *Cortex* 2014, 58, 281–288. [CrossRef]
99. Jacobs, C.; De Graaf, T.A.; Goebel, R.; Sack, A.T. The temporal dynamics of early visual cortex involvement in behavioral priming. *PLoS ONE* 2012, 7, e48808. [CrossRef]
100. Kongthong, N.; Minami, T.; Nakauchi, S. Semantic processing in subliminal face stimuli: An EEG and tDCS study. *Neurosci. Lett.* 2013, 544, 141–146. [CrossRef] [PubMed]
101. Meehan, S.K.; Zabukovec, J.R.; Dao, E.; Cheung, K.L.; Linsdell, M.A.; Boyd, L.A. One hertz repetitive transcranial magnetic stimulation over dorsal premotor cortex enhances offline motor memory consolidation for sequence-specific implicit learning. *Eur. J. Neurosci.* 2013, 38, 3071–3079. [CrossRef] [PubMed]
102. Cantone, M.; Di Pino, G.; Capone, F.; Piombo, M.; Chiarelli, D.; Cheeran, B.; Pennisi, G.; Di Lazzaro, V. The contribution of transcranial magnetic stimulation in the diagnosis and in the management of dementia. *Clin. Neurophysiol.* 2014, 125, 1509–1532. [CrossRef] [PubMed]

103. Harvey, P.O.; Lepage, M. Neural correlates of recognition memory of social information in people with schizophrenia. *J. Psychiatry Neurosci.* 2014, 39, 97–109. [CrossRef] [PubMed]
104. Koski, L.; Kolivakis, T.; Yu, C.; Chen, J.K.; Delaney, S.; Pito, A. Noninvasive brain stimulation for persistent postconcussive symptoms in mild traumatic brain injury. *J. Neurotrauma* 2014, 32, 38–44. [CrossRef]
105. Lett, T.A.; Voineskos, A.N.; Kennedy, J.L.; Levine, B.; Daskalakis, Z. Treating working memory deficits in schizophrenia: A review of the neurobiology. *Biol. Psychiatry* 2014, 75, 361–370. [CrossRef]
106. Leuchter, A.F.; Cook, I.A.; Jin, Y.; Philips, B. The relationship between brain oscillatory activity and therapeutic effectiveness of transcranial magnetic stimulation in the treatment of major depressive disorder. *Front. Hum. Neurosci.* 2013, 7, 37. [CrossRef]
107. Marin, M.F.; Camprodon, J.A.; Dougherty, D.D.; Milad, M.R. Device-based brain stimulation to augment fear extinction: Implications for PTSD treatment and beyond. *Depress. Anxiety* 2014, 31, 269–278. [CrossRef]
108. Nadeau, S.E.; Bowers, D.; Jones, T.L.; Wu, S.S.; Triggs, W.J.; Heilman, K.M. Cognitive effects of treatment of depression with repetitive transcranial magnetic stimulation. *Cogn. Behav. Neurol.* 2014, 27, 77–87. [CrossRef]
109. Wang, J.X.; Rogers, L.M.; Gross, E.Z.; Ryals, A.J.; Dokucu, M.E.; Brandstatt, K.L.; Hermiller, M.S.; Voss, J.L. Targeted enhancement of cortical-hippocampal brain networks and associative memory. *Science* 2014, 345, 1054–1057. [CrossRef]
110. Bilek, E.; Schäfer, A.; Ochs, E.; Esslinger, C.; Zangl, M.; Plichta, M.M.; Braun, U.; Kirsch, P.; Schulze, T.G.; Rietschel, M.; et al. Application of high-frequency repetitive transcranial magnetic stimulation to the DLPFC alters human prefrontal-hippocampal functional interaction. *J. Neurosci.* 2013, 33, 7050–7056. [CrossRef] [PubMed]
111. Censor, N.; Horowitz, S.G.; Cohen, L.G. Interference with existing memories alters offline intrinsic functional brain connectivity. *Neuron* 2014, 81, 69–76. [CrossRef] [PubMed]
112. Hanslmayer, S.; Matuschek, J.; Fellner, M.C. Entrainment of prefrontal beta oscillations induce an endogenous echo and impairs memory formation. *Curr. Biol.* 2014, 24, 9049. [CrossRef]
113. Van de Ven, V.; Sack, A.T. Transcranial magnetic stimulation of visual cortex in memory: Cortical state, interference and reactivation of visual content in memory. *Behav. Brain Res.* 2013, 236, 67–77. [CrossRef]
114. Zanto, T.P.; Chadick, J.Z.; Satris, G.; Gazzaley, A. Rapid functional reorganization in human cortex following neural perturbation. *J. Neurosci.* 2013, 33, 16268–16274. [CrossRef] [PubMed]
115. Batsikadze, G.; Paulus, W.; Kuo, M.F.; Nitsche, M.A. Effect of serotonin on paired associative stimulation-induced plasticity in the human motor cortex. *Neuropsychopharmacology* 2013, 38, 2260–2267. [CrossRef]
116. Chajeb, L.; Antal, A.; Ambrus, G.G.; Paulus, W. Brain-derived neurotrophic factor: Its impact upon neuroplasticity inducing transcranial brain stimulation protocols. *Neurogenetics* 2014, 15, 1–11. [CrossRef]
117. Ma, J.; Zhang, Z.; Kang, L.; Geng, D.; Wang, Y.; Wang, M.; Cui, H. Repetitive transcranial magnetic stimulation (rTMS) influences spatial cognition and modulates hippocampal structural synaptic plasticity in aging mice. *Exp. Gerontol.* 2014, 58, 256–268. [CrossRef]
118. Rogasch, N.C.; Daskalakis, Z.; Fitzgerald, P.B. Cortical inhibition of distinct mechanisms in the dorsolateral prefrontal cortex is related to working memory performance: A TMS-EEG study. *Cortex* 2014, 64C, 68–77. [CrossRef]
119. Tan, T.; Xie, J.; Liu, T.; Chen, X.; Zheng, X.; Tong, Z.; Tian, X. Low-frequency (1 Hz) repetitive transcranial magnetic stimulation (rTMS) reverses A $\beta$ (1-41)-mediated memory deficits in rats. *Exp. Gerontol.* 2013, 48, 786–794. [CrossRef]
120. Yang, H.; Shi, O.; Jin, Y.; Henrich-Noack, P.; Qiao, H.; Cai, C.; Tao, H.; Tian, X. Functional protection of learning and memory abilities in rats with vascular dementia. *Restor. Neurol. Neurosci.* 2014, 32, 689–700. [CrossRef]
121. Lindsey, A.; Ellison, R.A.H.; Aaronson, A.; Kletzel, S.; Stika, M.; Guernon, A.T. rTMS/iTBS and Cognitive Rehabilitation: A Theoretical Framework and Review Examining Paired Treatment to Remediate Deficits Associated with TBI and PTSD. *Neurosci. Biobehav. Rev.* (in press).
122. Fiske, A.; Henningsen, P.; Buyx, A. Your robot therapist will see you now: Ethical implications of embodied artificial intelligence in psychiatry, psychology, and psychotherapy. *J. Med. Internet Res.* 2019, 21, e13216. [CrossRef]
123. O'Sullivan, S.; Nevejans, N.; Allen, C.; Blyth, A.; Leonard, S.; Pagallo, U.; Holzinger, K.; Holzinger, A.; Sajid, M.I.; Ashrafian, H. Legal, regulatory, and ethical frameworks for development of standards in artificial intelligence (AI) and autonomous robotic surgery. *Int. J. Med. Robot.* 2019, 15, e1968. [CrossRef]
124. Evans, C.R.; Medina, M.G.; Dwyer, A.M. Telemedicine and telerobotics: From science fiction to reality. *Updates Surg.* 2018, 70, 357–362. [CrossRef] [PubMed]
125. Payne, C.; Guang-Zhong, Y. Hand-held medical robots. *Ann. Biomed. Eng.* 2014, 42, 1594–1605. [CrossRef]
126. Umay, I.; Fidan, B.; Barshan, B. Localization and tracking of implantable biomedical sensors. *Sensors* 2017, 17, 583. [CrossRef]



127. Vilela, M.; Hochberg, L.R. Applications of brain-computer interfaces to the control of robotic and prosthetic arms. *Handb. Clin. Neurol.* 2020, 168, 87–99. [CrossRef]
128. Bedi, G.; Carrillo, F.; Cecchi, G.A.; Slezak, D.F.; Sigman, M.; Mota, N.B.; Ribeiro, S.; Javitt, D.C.; Copelli, M.; Corcoran, C.M. Automated analysis of free speech predicts psychosis onset in high-risk youths. *Schizophrenia* 2015, 1, 15030. [CrossRef] [PubMed]
129. Clark, K.B. Evolution of affective and linguistic disambiguation under social eavesdropping pressures. *Behav. Brain Sci.* 2014, 37, 551–552. [CrossRef]
130. Clark, K.B. Dialect Structural Priming in Endangered Language Evolution, Devolution and Protection. *Proc. Roy. Soc. B. Biol. Sci.* eLetter2017. Available online: <https://royalsocietypublishing.org/doi/suppl/10.1098/rspb.2014.1574> (accessed on 10 December 2021).
131. Clark, K.B. Natural chunk-and-pass language processing: Just another joint source-channel coding model? *Commun. Integr. Biol.* 2018, 11, e1445899. [CrossRef] [PubMed]
132. Grabowski, K.; Rynkiewicz, A.; Lassalle, A.; Baron-Cohen, S.; Schuller, B.; Cummins, N.; Baird, A.; Podgórska-Bednarz, J.; Pieniazek, A.; Łucka, I. Emotional expression in psychiatric conditions: New technology for clinicians. *Psychiatry Clin. Neurosci.* 2019, 73, 50–62. [CrossRef]
133. Lake, B.M.; Ullman, T.D.; Tenenbaum, J.D.; Gershman, S.J. Building machines that learn and think like people. *Behav. Brain Sci.* 2017, 40, e253. [CrossRef] [PubMed]
134. Clark, K.B. Topical: Intelligent Meta-Learning Inferential Social Robotic and Virtual Space Medicine Clinicians. White Paper Submitted to the Committee on the Decadal Survey for Biological and Physical Sciences Research in Space 2023–2032; National Research Council: Washington, DC, USA, in press.
135. Mooney, S.J.; Pejaver, V. Big data in public health: Terminology, machine learning, and privacy. *Ann. Rev. Public Health* 2018, 39, 95–112. [CrossRef] [PubMed]



**INNO SPACE**  
SJIF Scientific Journal Impact Factor  
**Impact Factor: 8.118**



**ISSN** INTERNATIONAL  
STANDARD  
SERIAL  
NUMBER  
**INDIA**



# INTERNATIONAL JOURNAL OF INNOVATIVE RESEARCH

IN SCIENCE | ENGINEERING | TECHNOLOGY

 **9940 572 462**  **6381 907 438**  **ijirset@gmail.com**



[www.ijirset.com](http://www.ijirset.com)

Scan to save the contact details